Free Trial

Agile Therapeutics Q4 2023 Earnings Report

Agile Therapeutics EPS Results

Actual EPS
-$1.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Agile Therapeutics Revenue Results

Actual Revenue
$3.62 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Agile Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Agile Therapeutics Earnings Headlines

The Real Hillbilly Elegy
The mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky, Tennessee and beyond… It's one of our country’s most scenic areas. But hidden beneath the beauty is an ugly reality: our most beautiful land is also the poorest. It’s a tragedy because for over 200 years, generation after generation has worked “coal country” with nothing but a pick and shovel, hauling billions of dollars from the ground.
See More Agile Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agile Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agile Therapeutics and other key companies, straight to your email.

About Agile Therapeutics

Agile Therapeutics (NASDAQ:AGRX), a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

View Agile Therapeutics Profile

More Earnings Resources from MarketBeat